Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

Axxima Pharmaceuticals AG

Axxima Pharmaceuticals AG is a drug discovery and development company, pioneering the novel strategy of generating a “Signal Transduction Firewall” against infections and related diseases. By blocking critical signal transduction pathways required by pathogens for their survival, disease progression is prevented. The company is currently focussing on HIV, HCMV, Hepatitis B and C, Influenza and TB and has one compound in clinical development against highly resistant HIV strains. In three private financing rounds, Axxima has received a total of 56 million Euro from German and international investors, and currently employs a staff of 80.

Details


Adresse:
Axxima Pharmaceuticals AG

Am Klopferspitz 19
82152 Martinsried
Deutschland
Arbeitsgebiet:
Forschung & Lehre
Expansion:
international
Webseite:
Mitarbeiteranzahl:
51-500
Gründungsjahr:
1997